Ambrx Biopharma - AMAM Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $24.13
  • Forecasted Upside: -13.84%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$28.00
+0 (0.00%)
Get New Ambrx Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMAM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMAM

Analyst Price Target is $24.13
▼ -13.84% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for Ambrx Biopharma in the last 3 months. The average price target is $24.13, with a high forecast of $32.00 and a low forecast of $9.00. The average price target represents a -13.84% upside from the last price of $28.00.

This chart shows the closing price for AMAM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 investment analysts is to moderate buy stock in Ambrx Biopharma. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
11/1/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2024Robert W. BairdReiterated RatingOutperform ➝ Neutral$28.00Low
1/12/2024Cantor FitzgeraldReiterated RatingOverweightLow
1/10/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market PerformLow
1/9/2024B. RileyDowngradeBuy ➝ Neutral$26.00 ➝ $28.00Low
12/18/2023Cantor FitzgeraldReiterated RatingOverweightLow
11/29/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$15.00Low
11/20/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$15.00Low
11/15/2023The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$10.00 ➝ $9.00Low
11/14/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$33.00 ➝ $32.00Low
10/23/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$29.00 ➝ $33.00Low
10/23/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$25.00Low
9/25/2023JMP SecuritiesInitiated CoverageOutperform$15.00Low
9/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$25.00Low
9/13/2023The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$6.00 ➝ $10.00Low
9/12/2023BTIG ResearchInitiated CoverageBuy$26.00Low
8/16/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$25.00Low
7/31/2023Royal Bank of CanadaInitiated CoverageOutperform$29.00Low
6/13/2023B. RileyInitiated CoverageBuy$26.00Low
6/1/2023OppenheimerInitiated CoverageOutperform$30.00Low
5/19/2023Cantor FitzgeraldInitiated CoverageOverweight$25.00Low
4/5/2023Robert W. BairdBoost TargetOutperform$11.00 ➝ $12.00Low
3/3/2023Robert W. BairdBoost Target$4.00 ➝ $11.00Low
2/27/2023The Goldman Sachs GroupBoost TargetNeutral$2.00 ➝ $6.00Low
10/19/2022Robert W. BairdLower Target$8.00 ➝ $4.00Low
9/21/2022Robert W. BairdLower Target$16.00 ➝ $8.00Low
5/24/2022The Goldman Sachs GroupLower TargetNeutral$6.00 ➝ $4.00High
4/6/2022Robert W. BairdInitiated CoverageOutperform$16.00High
2/28/2022The Goldman Sachs GroupInitiated CoverageNeutral$6.00Low
7/13/2021CowenInitiated CoverageOutperform$21.30High
7/13/2021Bank of AmericaInitiated CoverageBuy$26.00High
7/13/2021The Goldman Sachs GroupInitiated CoverageBuy$53.00High
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/27/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/26/2023
  • 8 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/25/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Ambrx Biopharma logo
Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.
Read More

Today's Range

Now: $28.00
Low: $28.00
High: $28.00

50 Day Range

MA: $27.94
Low: $27.70
High: $28.00

52 Week Range

Now: $28.00
Low: $6.55
High: $28.15

Volume

N/A

Average Volume

2,123,967 shs

Market Capitalization

$1.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Ambrx Biopharma?

The following Wall Street analysts have issued reports on Ambrx Biopharma in the last year: B. Riley, BTIG Research, Cantor Fitzgerald, JMP Securities, Oppenheimer Holdings Inc., Robert W. Baird, Royal Bank of Canada, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for AMAM.

What is the current price target for Ambrx Biopharma?

8 Wall Street analysts have set twelve-month price targets for Ambrx Biopharma in the last year. Their average twelve-month price target is $24.13, suggesting a possible downside of 13.8%. Royal Bank of Canada has the highest price target set, predicting AMAM will reach $32.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $9.00 for Ambrx Biopharma in the next year.
View the latest price targets for AMAM.

What is the current consensus analyst rating for Ambrx Biopharma?

Ambrx Biopharma currently has 4 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AMAM.

What other companies compete with Ambrx Biopharma?

How do I contact Ambrx Biopharma's investor relations team?

The company's listed phone number is 858-875-2400 and its investor relations email address is [email protected]. The official website for Ambrx Biopharma is ambrx.com. Learn More about contacing Ambrx Biopharma investor relations.